Bli medlem
Bli medlem

Du är här

2021-07-22

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good half-year results

Basel, 22 July 2021

  • Group sales up 8%1 at constant exchange rates (CER); 5% in Swiss francs
  • Pharmaceuticals Division sales decline 3%; sales grow 4% in the second quarter, following a first-quarter decrease of 9%; newly launched medicines (+30%) compensate for the continued impact from biosimilars
  • Diagnostics Division sales grow 51% due to high demand for COVID-19 tests and strong momentum in routine testing
  • IFRS net income increases by 2% (-3% in Swiss francs), while core earnings per share up 6%
  • Highlights in the second quarter:
    • Pipeline: Positive study results for immunotherapy Tecentriq in early lung cancer; encouraging data strengthen Roche’s portfolio in neurosciences and hard-to-treat blood cancers
    • EU approvals: Tecentriq (specific type of metastatic non-small cell lung cancer), Venclyxto-based combinations (acute myeloid leukaemia) and Enspryng (neuromyelitis optica spectrum disorder, a rare autoimmune disease of the CNS)
    • GenMark Diagnostics: Acquisition, completed in April, broadens Roche’s molecular lab portfolio and reinforces our commitment to fight infectious diseases and antibiotic resistance
    • COVID-19: Additional positive study results for antibody combination Ronapreve (co-developed with Regeneron) and AT-527 (co-developed with Atea); Japan becomes first country to approve Ronapreve for the treatment of mild to moderate COVID-19; FDA Emergency Use Authorization for Actemra/RoActemra; launch of further tests reinforces Roche’s position as a global leader in COVID-19 diagnostics
  • Outlook for 2021 confirmed
Key figures CHF millions % change
January - June 2021 2021 2020 At CER1 In CHF
Group sales 30,713 29,281 8 5
Pharmaceuticals Division 21,671 23,202 -3
Författare GlobeNewswire

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.